Bio-Rad Labs (BIO) Misses Q3 EPS by 46c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts BIO Hot Sheet
Price: $365.12 +0.45%
Revenue Growth %: -0.5%
Financial Fact:
Net income including noncontrolling interests: 0
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: -0.5%
Financial Fact:
Net income including noncontrolling interests: 0
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Bio-Rad Labs (NYSE: BIO) reported Q3 EPS of $0.40, $0.46 worse than the analyst estimate of $0.86. Revenue for the quarter came in at $530.6 million versus the consensus estimate of $525.4 million.
For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI-powered cyber threats light a fire under cybersecurity stocks
- Bristol Myers Squibb MS CAR T therapy data shows patients off DMTs
- Honeywell International (HON) PT Raised to $256 at Bernstein SocGen Group
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
